The US Food and Drug Administration (FDA) granted emergency use authorization for the COVID-19 vaccine produced in the Pfizer-BioNTech subsidiary in December. Since then, the vaccine American citizens aged 16 and over
It was applicable for . Against the new type of coronavirus disease providing 94 to 95 percent defense a valuable step has been passed for the vaccine.
According to Reuters, the U.S. Food and Drug Administration has approved the Pfizer-BioNTech vaccine. approved for full use. Public health officials, who made a statement after the decision in question, stated that they hoped that the Americans who have not had the vaccine now will be convinced that this vaccine is reliable and effective.
Pfizer-BioNTech vaccine expected to increase confidence
Janet Woodcock, Acting Leader of the US Food and Drug Administration, made a statement on the subject. “While millions of people have had their COVID-19 vaccines in a believable form, we are aware that for some, FDA approval of a vaccine may provide additional faith,” Woodcock said.
In emergencies such as a pandemic, countries are trying to speed up the effort with the epidemic. To Emergency Use Authorization (EUA) they have. A vaccine provides where the benefit is greater than the waste If it is scientifically proven, at this point, the manufacturer and the vaccine can be given an Emergency Use Authorization by the relevant institutions. Currently, only Pfizer-BioNTech has passed the full approval phase of the vaccines that have received this authorization. The FDA has yet to make an announcement for the others.
The official name of the vaccine is ‘Comirnaty’
Following the approval of the Food and Drug Administration, the statement from Pfizer CEO Albert Bourla was not delayed. Stating that the approval is based on the latest information obtained from the clinical trials of the vaccine, Bourla said, “Today’s approval for those aged 16 and over confirms the efficacy and safety profile of our vaccine at a time when it is urgently needed.”
In addition, the official name of the vaccine Comirnaty and will now be marketed as such.